文献速递艾滋病与性传播感染

戒烟对HIV感染者癌症发病率的影响:抗HIV药物不良事件数据收集研究

Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该研究随访35442名HIV感染者共309803人年,评估戒烟后癌症发病率变化。戒烟后<1年全癌发病率高于从不吸烟者(aIRR 1.66),1-1.9年后与从不吸烟者无显著差异;肺癌在戒烟<1年时aIRR达19.08,戒烟5年后仍为8.69。结论为HIV感染者戒烟5年后肺癌风险仍升高,应优先开展戒烟工作。

要点

  • 戒烟后<1年全癌发病率高于从不吸烟者(aIRR 1.66,95%CI 1.37-2.02)。
  • 戒烟1-1.9年后全癌发病率与从不吸烟者无显著差异。
  • 戒烟5年后肺癌发病率仍为从不吸烟者的8.69倍(95%CI 3.40-22.18)。

核心结论

  • HIV感染者戒烟5年后肺癌发病率仍高于从不吸烟者。
  • 应优先开展预防吸烟起始和戒烟工作以降低未来癌症风险。

研究设计与样本

  • 来自抗HIV药物不良事件数据收集(D:A:D)研究的前瞻性队列分析。
  • 共纳入35442人,随访309803人年,从2004年1月1日至首次癌症诊断、死亡或2016年2月1日。
  • 吸烟状态分为戒烟者、当前吸烟者和从不吸烟者,采用泊松回归计算调整发病率比(aIRR),调整人口学和临床因素。

主要发现

  • 基线时当前吸烟者占49%,戒烟者占21%,从不吸烟者占30%。
  • 全癌合计2183例,戒烟<1年者较从不吸烟者aIRR为1.66(95%CI 1.37-2.02),戒烟1-1.9年后与从不吸烟者无显著差异。
  • 肺癌271例,戒烟<1年者aIRR为19.08(95%CI 8.10-44.95),戒烟5年后aIRR仍为8.69(95%CI 3.40-22.18)。
  • 其他吸烟相关癌症622例,戒烟第一年aIRR为2.06(95%CI 1.42-2.99),此后降至与不吸烟者相似水平。

临床怎么用

  • 作者认为应优先开展预防吸烟起始和戒烟工作,以降低HIV感染者未来癌症风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancers are a major source of morbidity and mortality for human immunodeficiency virus (HIV)-infected persons, but the clinical benefits of smoking cessation are unknown. METHODS: Participants were followed from 1 January 2004 until first cancer diagnosis, death, or 1 February 2016. Smoking status was defined as ex-smoker, current smoker, and never smoker. Adjusted incidence rate ratios (aIRRs) were calculated using Poisson regression, adjusting for demographic and clinical factors. RESULTS: In total 35442 persons from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study contributed 309803 person-years of follow-up. At baseline, 49% were current smokers, 21% were ex-smokers, and 30% had never smoked. Incidence of all cancers combined (n = 2183) was highest <1 year after smoking cessation compared to never smokers (aIRR, 1.66 [95% confidence interval {CI}, 1.37-2.02]) and not significantly different from never smokers 1-1.9 years after cessation. Lung cancer incidence (n = 271) was elevated <1 year after cessation (aIRR, 19.08 [95% CI, 8.10-44.95]) and remained 8-fold higher 5 years after smoking cessation (aIRR, 8.69 [95% CI, 3.40-22.18]). Incidence of other smoking-related cancers (n = 622) was elevated in the first year after cessation (aIRR, 2.06 [95% CI, 1.42-2.99]) and declined to a level similar to nonsmokers thereafter. CONCLUSIONS: Lung cancer incidence in HIV-infected individuals remained elevated >5 years after smoking cessation. Deterring uptake of smoking and smoking cessation efforts should be prioritised to reduce future cancer risk.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Shepherd L, Ryom L, Law M, et al. Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clin Infect Dis. 2019. PMID: 29912335. doi:10.1093/cid/ciy508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。